China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US partner Slate Run Pharmaceuticals and Premier, Inc. (NASDAQ: PINC), a healthcare-focused group purchasing organization (GPO) in the US. The collaboration centers on contrast agents.
Partnership Details
Under the agreement, Premier’s members have the freedom to purchase iopamidol, gadobutrol, gadoteric acid meglumine salt, and gadoteridol using pre-signed prices and terms. Poly anticipates gaining a market share of over 10% through this partnership, with expectations of including more contrast agent varieties in the future.-Fineline Info & Tech
Leave a Reply